Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More


Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.

Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The challenge now falls to Lilly (NYSE: LLY) to find the... Read more »

Reprints | Share:          E-mail
UNDERWRITERS AND PARTNERS

          

          

            

Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders, Life Sciences, Clinical Trials, Genentech, Elijah Cummings, Amgen, Type 1 Diabetes, Eli Lilly, Schrodinger, Adaptive Biotechnologies, Wuxi Apptec, Takeda Pharmaceutical, Scott Gottlieb, National blog main, New York blog main, New York top stories, Seattle blog main, Seattle top stories, Boston blog main, National top stories, San Francisco blog main, San Francisco top stories, Texas blog main, Texas top stories, Boston top stories, Detroit blog main, Detroit top stories, Raleigh-Durham blog main, San Diego blog main, San Diego top stories, Wisconsin blog main, Wisconsin top stories, Boulder/Denver blog main, Bristol-myers Squibb, Boulder/Denver top stories, Raleigh-Durham top stories, Indiana blog main, Sage Therapeutics, Indiana top stories, Beta bionics, Loxo Oncology, Loxo, Drug Prices, Generic Drugs, UroGen Pharma, Romosozumab, Cancer Drugs, Lilly NYSE, Providence Ventures, Alector, Providence St. Joseph Health, J.P. Morgan Healthcare Conference, Poseida Therapeutics, Civica Rx, Black Diamond Therapeutics, Apollomics, Bill & Melinda Gates Foundation Trust, Diabets, Upper Tract Urothelial Cancer, Loxo Oncology Loxo NASDAQ

Source:  https://xconomy.com/national/2019/01/11/bio-roundup-jpm19-notes-loxo-buyout-black-diamonds-cash-more/




Related:
October 10, 2017 at 6:30 AM Black Fellowship Students Headed From HBCUs to VC Boardrooms
October 9, 2017 at 5:10 AM Steve Case’s Rise of the Rest Shines Spotlight on Emerging Tech Hubs
August 10, 2017 at 6:00 AM Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists
October 6, 2016 at 12:01 AM Third-Quarter Report Shows Slowdown in VC Activity, & Top 10 Deals
September 30, 2016 at 10:25 AM Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More